Amyotrophic Lateral Sclerosis Therapeutic Pipeline Market 2017 Key Players Orphazyme ApS, ApoPharma Inc and BioHealthonomics Inc, Says a New Research Report at RnRMarketResearch.com

USA - English

• India - English

PUNE, India, May 31, 2017 /PRNewswire/ --

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017 is new research report adds on RnRMarketResearch.com includes 455 pages with latest updates, data and information to its online business intelligence library.

Latest report "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017", provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Complete report on Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017 spread across 455 pages is available at http://www.rnrmarketresearch.com/amyotrophic-lateral-sclerosis-pipeline-review-h1-2017-market-report.html .

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019641. (This report is available at up to 25% Discount till June 02nd 2017.)

Main key players of Amyotrophic Lateral Sclerosis pipeline are 2-BBB Medicines BV, AB Science SA, Anavex Life Sciences Corp, Angion Biomedica Corp, Apogenix GmbH, ApoPharma Inc, ArmaGen Inc, Avanir Pharmaceuticals Inc, BioCrea GmbH, Biogen Inc, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Catabasis Pharmaceuticals Inc, Chronos Therapeutics Ltd, ContraVir Pharmaceuticals Inc, Corcept Therapeutics Inc, Corestem Inc, Cytokinetics Inc, Daval International Ltd, Edison Pharmaceuticals Inc, Eisai Co Ltd, Ensemble Therapeutics Corp, Evotec AG, F. Hoffmann-La Roche Ltd,

Flex Pharma Inc, FPRT Bio Inc, Gemac SA, Genentech Inc, Genervon Biopharmaceuticals LLC, GeNeuro SA more..

The Amyotrophic Lateral Sclerosis pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System). The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Related reports on Amyotrophic Lateral Sclerosis is Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017

The Report "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.

About Us:

RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Contact:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: +1-888-391-5441
E-mail: [email protected]

SOURCE RnRMarketResearch